| 主な論文 |
- Ikeda M, Taniguchi-Ikeda M, Kato T, Shinkai Y, Tanaka S, Hagiwara H, Sasaki N, Masaki T, Matsumura K, Sonoo M, Kurahashi H, Saito F. Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach. Molecular therapy. Methods & clinical development 18:131-144, 2020 https://doi.org/10.1016/j.omtm.2020.05.024
- 相原正博，萩原宏毅．不活動が脳に与える影響の基礎的検討－脳由来神経栄養因子BDNFに着目して－．平成30年度理学療法にかかわる研究助成 研究助成報告書．2019 http://jspt.japanpt.or.jp/support/
- Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2018;0:1–8. doi:10.1136/jnnp-2018-317964.
- Katsuta W, Aihara M, Hirose N. Saito F, Hagiwara H. Changes in oxidative stress severity and antioxidant potential during muscle atrophy and reloading in mice. Journal of Physical Therapy Science 30(1): 42–46, 2018
- Fukai Y, Ohsawa Y, Ohtsubo H, Nishimatsu SI, Hagiwara H, Noda M, Sasaoka T, Murakami T, Sunada Y. Cleavage of -ystroglycan occurs in sarcoglycan-deficient skeletal muscle without MMP-2 and MMP-9. Biochem Biophys Res Commun. 492(2):199-205, 2017
- Aihara M, Hirose N, Katsuta W, Saito F, Maruyama H, Hagiwara H. A new model of skeletal muscle atrophy induced by immobilization using a hook-and-loop fastener in mice. Journal of Physical Therapy Science 29(10):1779–1783, 2017
- Huang S, Hagiwara H, Shimizu T, Wang W. Pax3 preserves myoblasts undifferentiated by suppressing MyoD and enhancing cell cycle regulators. International journal of clinical and experimental pathology 10(3):3043-3051, 2017.
- Ohsawa Y, Takayama K, Nishimatsu S, Okada T, Fujino M, Fukai Y, Murakami T, Hagiwara H, Itoh F, Tsuchida K, Hayashi Y, Sunada Y. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy. PLoS One 10(7):e0133713, 2015. doi: 10.1371/journal.pone.0133713. eCollection 2015.
- Saito F, Kanagawa M, Ikeda M, Hagiwara H, Masaki T, Ohkuma H, Shimizu T, Sonoo M, Toda T, Matsumura K. Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice. Human Molecular Genetics 23(17):4543-4558, 2014
- 萩原宏毅, 塚田絵里子：神経リハビリテーションの現状と展望．帝京科学大学紀要．8:1-10, 2012
- Amenta A, Creely H, Mercado MLT, Hagiwara H, McKechnie B, Lechner B, Rossi S, Wang Q, Owens R, Marrero E, Mei L, Hoch W, Young M, McQuillan D, Rotundo R, Fallon J. Biglycan is an extracellular MuSK binding protein important for synapse stability. The Journal of Neuroscience 32(7):2324-2334, 2012
- Hagiwara H, Saito F, Masaki T, Ikeda M, Nakamura-Okuma A, Shimizu T, Matsumura K. Histone deacetylase inhibitor trichostatin A enhances myogenesis by coordinating muscle regulatory factors and myogenic repressors. Biochem Biophys Res Commun. 414:826-831, 2011
- Saito F, Saito-Arai Y, Nakamura-Okuma A, Ikeda M, Hagiwara H, Masaki T, Shimizu T, Matsumura K. Secretion of N-terminal domain of a-dystroglycan in cerebrospinal fluid. Biochem Biophys Res Commun. 411:365-369, 2011
- 萩原宏毅, 松村喜一郎：筋ジストロフィー治療薬としてのヒストン脱アセチル化酵素阻害剤－臨床応用への展望．帝京医学雑誌．34(4):303-313, 2011
- Hagiwara H, Nakamura A, Matsumura K. Histone deacetylase inhibitors as therapeutic targets for muscular dystrophy. Current Trends in Neurology. 4：71-80, 2011
- Hagiwara H, Matsumura K. Dystroglycan, a multifunctional adaptor protein for signal transduction and a potential therapeutic target. Current Signal Transduction Therapy. 6:71-81, 2011
- 斉藤史明, 松村喜一郎, 中村文美, 池田美樹, 張欣, 萩原宏毅, 清水輝夫：ジストログリカンの機能と神経筋疾患の分子病態への関わり．帝京医学雑誌．32(5):307-317, 2009
- 斉藤史明，松村喜一郎，萩原宏毅，清水輝夫. 先天性筋ジストロフィーと a-dystroglycanopathy．臨床神経学48:543-549, 2008
- 萩原宏毅, 清水輝夫. 筋ジストロフィー現在と未来．分子病態と臨床．その他の筋ジストロフィー (インテグリン，デスミン，クリスタリン，プレクチンなど). Clinical Neuroscience 26(2):181-184, 2008
|
